Skip to main content

Table 3 Cost-utility analysis results from comparing paliperidone and risperidone long acting injections for chronic schizophrenia in Greece

From: Pharmacoeconomic analysis of paliperidone palmitate for treating schizophrenia in Greece

Drug

Total cost per patient*

Total QALYs per patient

Incremental cost per patient

Incremental QALYs per patient

Economic conclusion

PP-LAI

€3,529

0.840

-€166

0.025

dominant

RIS-LAI

€3,695

0.815

  

dominated

  1. LAI long acting injectable, PP paliperidone palmitate, RIS risperidone microspheres, QALY quality adjusted life years.
  2. *All costs are in 2011 Euros.